[A22-51] Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 20.10.2022
Project no.:
A22-51
Commission:
Commission awarded on 29.04.2022 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
- Premenopausal women: hint of minor added benefit
- Postmenopausal women: added benefit not proven
- Men: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-10-10.
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.